INTRODUCTION: Patients with localised and locally advanced renal cancer experience about 20% recurrence during a five-year follow-up period. The aim of the present study was to report recurrence rates and survival in a Danish population with renal cancer. METHODS: Data on patients diagnosed with renal cell carcinoma (RCC) at our institute from January 2005 to December 2013 were collected retrospectively. RESULTS: Overall, 367 patients were diagnosed with RCC during the period, and 78 patients (21%) presented with metastasis. The mean follow-up period for all patients was 41 months (standard deviation = 29, 95% confidence interval: 38-44). The total recurrence rates (RRs) at one, three and five years were 4.5%, 13.5% and 22.3%, respectively. Overall survival rates in the patients who underwent surgery with localised and locally advanced disease were 96.1%, 88.2% and 78.3% for one, three and five years, respectively. The mean time to first recurrence was 26.6 months. The one-year RR was 1.2%, 5.5% and 13.8% for low, intermediate and high-risk Leibovich scores, respectively. The three-year RR was 8.3%, 14.1% and 29.6% for low, intermediate and high-risk Leibovich scores, respectively; and the five-year RR was 12.0%, 26.6% and 52.9% for low, intermediate and high-risk Leibovich scores, respectively. CONCLUSIONS: RRs after localised and locally advanced RCC was 22%. According to the risk of recurrence, we recommend a follow-up programme after nephrectomy with computed tomography every second year for low-risk patients, annually for intermediate-risk patients and every six months for high-risk patients. FUNDING: none. TRIAL REGISTRATION: none.
INTRODUCTION:Patients with localised and locally advanced renal cancer experience about 20% recurrence during a five-year follow-up period. The aim of the present study was to report recurrence rates and survival in a Danish population with renal cancer. METHODS: Data on patients diagnosed with renal cell carcinoma (RCC) at our institute from January 2005 to December 2013 were collected retrospectively. RESULTS: Overall, 367 patients were diagnosed with RCC during the period, and 78 patients (21%) presented with metastasis. The mean follow-up period for all patients was 41 months (standard deviation = 29, 95% confidence interval: 38-44). The total recurrence rates (RRs) at one, three and five years were 4.5%, 13.5% and 22.3%, respectively. Overall survival rates in the patients who underwent surgery with localised and locally advanced disease were 96.1%, 88.2% and 78.3% for one, three and five years, respectively. The mean time to first recurrence was 26.6 months. The one-year RR was 1.2%, 5.5% and 13.8% for low, intermediate and high-risk Leibovich scores, respectively. The three-year RR was 8.3%, 14.1% and 29.6% for low, intermediate and high-risk Leibovich scores, respectively; and the five-year RR was 12.0%, 26.6% and 52.9% for low, intermediate and high-risk Leibovich scores, respectively. CONCLUSIONS: RRs after localised and locally advanced RCC was 22%. According to the risk of recurrence, we recommend a follow-up programme after nephrectomy with computed tomography every second year for low-risk patients, annually for intermediate-risk patients and every six months for high-risk patients. FUNDING: none. TRIAL REGISTRATION: none.
Authors: Wassim Kassouf; Leonardo L Monteiro; Darrel E Drachenberg; Adrian S Fairey; Antonio Finelli; Anil Kapoor; Jean-Baptiste Lattouf; Michael J Leveridge; Nicholas E Power; Frederic Pouliot; Ricardo A Rendon; Robert Sabbagh; Alan I So; Simon Tanguay; Rodney H Breau Journal: Can Urol Assoc J Date: 2018-05-31 Impact factor: 1.862
Authors: Thenappan Chandrasekar; Zachary Klaassen; Hanan Goldberg; Rashid K Sayyid; Girish S Kulkarni; Neil E Fleshner Journal: Oncotarget Date: 2018-03-30
Authors: M Maas; E G Klompenhouwer; D J van der Reijd; T R Baetens; F Gomez Munoz; B M Aarts; M J Lahaye; N M Graafland; C A R Lok; A G J Aalbers; N F M Kok; R G H Beets-Tan Journal: Abdom Radiol (NY) Date: 2022-07-02